Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Subscribe To Our Newsletter & Stay Updated
